tSYNCHRON
Tokenised Economic Right (not equity) to potential future liquidity from WLTH’s (Metamasters DAO Corp) allocation in Synchron. Slices are not securities of, nor endorsed by, the underlying company. They are unsecured contractual rights against WLTH (Metamasters DAO Corp). Residents of the U.S., UK, EU, and other restricted jurisdictions are ineligible. Review the full Terms & Conditions before purchasing.
Category: Brain computer interfaces
Stage: Pre-IPO
Opportunity Type: Tokenised Economic Right
Company Overview
Synchron develops the Stentrode, an endovascular brain-computer interface system implanted via the jugular vein into a blood vessel near the motor cortex. The system includes a 16-electrode array, a chest-implanted pulse generator, and a wireless data pathway that interfaces with consumer devices including iPhone, iPad, Alexa, and OpenAI-enabled assistants. Headquarters: Brooklyn, NY. CEO: Thomas Oxley.
The Problem
Patients with severe paralysis from ALS, stroke, spinal cord injuries, and neuromuscular diseases lack scalable solutions for digital communication and device control. Existing high-bandwidth BCIs require craniotomies, robotic surgery, and specialized neurosurgical centers, limiting access and increasing risk.
The Solution
Synchron’s Stentrode provides a minimally invasive BCI delivered via blood vessels using standard interventional radiology tools. The procedure takes approximately two hours, requires no open-brain surgery, and typically discharges patients within one to two days. Patients complete a 15–20 minute calibration and then can type at 5–10 words per minute, control cursors, and operate digital or smart-home systems through thought-based commands.
Founding Team
Thomas Oxley, MD, PhD, serves as CEO. Additional founding-team details were not included in the provided document, and no further verifiable information is available without adding unsupported content.
Business Model
The company uses a B2B medical device commercial model targeting hospitals and health systems. Pricing is projected to begin at USD ~60,000 per device, with ongoing software and clinical support. Synchron leverages existing catheter-lab infrastructure to scale like cardiac stents, avoiding neurosurgical robotics. The cloud-based ML system enables long-term recurring revenue as decoding models improve with data volume. Synchron holds an equity stake in Acquandas to secure supply of ultra-thin nitinol electrode components.
Traction and Validation
Synchron has implanted Stentrode devices in human patients and demonstrated digital-device control for ALS and paralysis patients. It is integrated with Apple’s BCI protocol for iOS control and Amazon Alexa for home automation. Early performance supports 5–10 words per minute typing through thought alone. The company has completed multiple funding rounds, including the 2025 USD 200 million Series D led by Double Point Ventures.
Intellectual Property and Strategic Assets
• Exclusive positioning as the pioneer of endovascular BCI implantation with no craniotomy. • Equity stake in Acquandas securing supply-chain control for nitinol micro-fabricated electrodes. • Integrations with Apple, Amazon, Nvidia, and OpenAI that create defensibility and ecosystem lock-in. • Cloud-based neural data network enabling continuous ML-driven decoder improvements across all patients.
Disclaimer
No affiliation — nominative reference only.
The underlying company is entirely unaffiliated with this offering, with Metamasters DAO Corp, and with the associated Slices. Specifically:
No endorsement or authorisation. The underlying company has not reviewed, approved, authorised, endorsed, sponsored, or consented to any aspect of this token, marketing material, or structure.
No participation or cooperation. The underlying company and its officers, directors, shareholders, and employees are not involved—directly or indirectly—in structuring, issuing, marketing, managing, servicing, or redeeming the Slices.
No contractual or economic relationship. Purchasing a Slice does not give you any equity, debt, contractual claim, option, warrant, or other right against the underlying company. Your sole counter-party is WLTH.
No obligations on the underlying company. It owes you no fiduciary duty, payment, or disclosure and will have no liability to you in connection with your purchase.
No effect on the underlying company’s securities. Issuing Slices does not affect its capitalisation, shareholder base, voting power, or governance.
Trademark usage. Any mention of the underlying company’s name is strictly nominative. WLTH claims no ownership and implies no sponsorship.
Information limitations. All company-related data herein are drawn from public sources WLTH believes to be reliable.
Last updated